These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 17467579)

  • 41. Noninvasive structural, functional, and molecular imaging in drug development.
    Rudin M
    Curr Opin Chem Biol; 2009 Jun; 13(3):360-71. PubMed ID: 19447067
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Driving drug discovery and patient therapy via the encapsulation and fusion of knowledge.
    Collins MA; Shaw I; Billington DC
    Drug Des Discov; 1999 Nov; 16(3):181-94. PubMed ID: 10624564
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Biochemical markers and the FDA Critical Path: how biomarkers may contribute to the understanding of pathophysiology and provide unique and necessary tools for drug development.
    Karsdal MA; Henriksen K; Leeming DJ; Mitchell P; Duffin K; Barascuk N; Klickstein L; Aggarwal P; Nemirovskiy O; Byrjalsen I; Qvist P; Bay-Jensen AC; Dam EB; Madsen SH; Christiansen C
    Biomarkers; 2009 May; 14(3):181-202. PubMed ID: 19399662
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A taste of the future.
    Sheridan C
    Nat Biotechnol; 2004 Oct; 22(10):1203-5. PubMed ID: 15470447
    [No Abstract]   [Full Text] [Related]  

  • 45. All systems go?
    Watson C
    Drug Discov Today; 2004 Dec; 9(24):1040-2. PubMed ID: 15582791
    [No Abstract]   [Full Text] [Related]  

  • 46. Translating in vivo diagnostics into clinical reality.
    Frangioni JV
    Nat Biotechnol; 2006 Aug; 24(8):909-13. PubMed ID: 16900127
    [No Abstract]   [Full Text] [Related]  

  • 47. Opportunities and challenges in the discovery of new central nervous system drugs.
    Krause JE; Chenard BL
    Ann N Y Acad Sci; 2008 Nov; 1144():243-50. PubMed ID: 19076381
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Progress in pharmacogenomics and its promise for medicine.
    Blake CA; Sobel BE
    Exp Biol Med (Maywood); 2008 Dec; 233(12):1482-3. PubMed ID: 18849537
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A case study of lean drug discovery: from project driven research to innovation studios and process factories.
    Ullman F; Boutellier R
    Drug Discov Today; 2008 Jun; 13(11-12):543-50. PubMed ID: 18549982
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Allocation of control rights and cooperation efficiency in public-private partnerships: theory and evidence from the Chinese pharmaceutical industry.
    Zhang Z; Jia M; Wan D
    Int J Health Care Finance Econ; 2009 Jun; 9(2):169-82. PubMed ID: 19360467
    [TBL] [Abstract][Full Text] [Related]  

  • 51. So, you want to work in industry?
    Lackie J
    Biologist (London); 2000 Nov; 47(5):243-6. PubMed ID: 11153131
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Personalized medicine: elusive dream or imminent reality?
    Lesko LJ
    Clin Pharmacol Ther; 2007 Jun; 81(6):807-16. PubMed ID: 17505496
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Early integration of pharmacokinetic and dynamic reasoning is essential for optimal development of lead compounds: strategic considerations.
    Gabrielsson J; Dolgos H; Gillberg PG; Bredberg U; Benthem B; Duker G
    Drug Discov Today; 2009 Apr; 14(7-8):358-72. PubMed ID: 19162219
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Drug discovery beyond the 'rule-of-five'.
    Zhang MQ; Wilkinson B
    Curr Opin Biotechnol; 2007 Dec; 18(6):478-88. PubMed ID: 18035532
    [TBL] [Abstract][Full Text] [Related]  

  • 55. High dose selection in general toxicity studies for drug development: A pharmaceutical industry perspective.
    Buckley LA; Dorato MA
    Regul Toxicol Pharmacol; 2009 Aug; 54(3):301-7. PubMed ID: 19477212
    [TBL] [Abstract][Full Text] [Related]  

  • 56. From pharmacogenomics to translational biomarkers.
    Mendrick DL
    Methods Mol Biol; 2008; 460():195-220. PubMed ID: 18449489
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The state of innovation in drug development.
    Kola I
    Clin Pharmacol Ther; 2008 Feb; 83(2):227-30. PubMed ID: 18202690
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A translational approach to detecting drug-induced cardiac injury with cardiac troponins: consensus and recommendations from the Cardiac Troponins Biomarker Working Group of the Health and Environmental Sciences Institute.
    Berridge BR; Pettit S; Walker DB; Jaffe AS; Schultze AE; Herman E; Reagan WJ; Lipshultz SE; Apple FS; York MJ
    Am Heart J; 2009 Jul; 158(1):21-9. PubMed ID: 19540388
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Use of ex vivo systems for biomarker discovery.
    Lavallie ER; Dorner AJ; Burczynski ME
    Curr Opin Pharmacol; 2008 Oct; 8(5):647-53. PubMed ID: 18771752
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.